Patents Assigned to AbbVie Inc.
  • Methods to control protein heterogeneity
    Patent number: 9234033
    Abstract: The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: January 12, 2016
    Assignee: AbbVie, Inc.
    Inventors: Lisa M. Rives, Cornelia Bengea, Xiaobei Zeng
  • TNF-? binding proteins
    Patent number: 9226983
    Abstract: Isolated binding proteins, e.g., antibodies or antigen binding portions thereof, which bind to tumor necrosis factor-alpha (TNF-?), e.g., human TNF-?, and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: April 6, 2011
    Date of Patent: January 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Lorenzo Benatuil, Tariq Ghayur, Carrie L. Goodreau, Peter C. Isakson, Jochen Salfeld
  • Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
    Patent number: 9227963
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: November 17, 2014
    Date of Patent: January 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew J. Souers
  • Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
    Patent number: 9227930
    Abstract: The present invention relates to aminoindane derivatives of the formula (I) or a physiologically tolerated salt thereof. The invention relates to pharmaceutical compositions comprising such aminoindane derivatives, and the use of such aminoindane derivatives for therapeutic purposes. The aminoindane derivatives are GlyT1 inhibitors.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: January 5, 2016
    Assignees: AbbVie Inc., AbbVie Deutschland GmbH & Co. KG
    Inventors: Frauke Pohlki, Udo Lange, Wilhelm Amberg, Michael Ochse, Berthold Behl, Charles W. Hutchins
  • Extended release hydrocodone acetaminophen and related methods and uses thereof
    Patent number: 9226907
    Abstract: The present invention generally provides a method of treatment and improvement of quality of life for patients adversely affected by various pain conditions. One preferred embodiment provides a method of treatment of acute pain, moderate to moderately severe pain, chronic pain, non-cancer pain, osteoarthritic pain, bunionectomy pain or lower back pain in a patient in need thereof, comprising providing at least one or two dosage form having about 15 mg of hydrocodone and its salt and about 500 mg of acetaminophen, once, twice or thrice daily. Preferably, the dosage form is about 30 mg of hydrocodone and about 1000 mg of acetaminophen taken twice daily. Alternatively, the dosage form is about 15 mg of hydrocodone and about 500 mg of acetaminophen taken twice daily.
    Type: Grant
    Filed: February 4, 2009
    Date of Patent: January 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Rita I. Jain, Andrea E. Best, Earle Lockhart, Steven E. Marx, James W. Thomas, Pamela Giang Vo
  • Process for preparing bicyclic amine derivatives
    Patent number: 9227901
    Abstract: The present invention provides a process for preparing a bicyclic amine derivative of the formula (Ia) or (Ib), comprising the rhodium-catalyzed asymmetric hydrogenation of an enamine of the formula (II), in the presence of a chiral ligand, wherein the chiral ligand is a chiral phosphine ligand.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: January 5, 2016
    Assignee: AbbVie Inc.
    Inventors: Yi-Yin Ku, Steven Hannick, Ashok K. Gupta
  • Process for preparing antiviral compound
    Patent number: 9216952
    Abstract: This invention is directed to: (a) processes for preparing a compound and salts thereof that, inter alia, are useful for inhibiting hepatitis C virus (HCV); (b) intermediates useful for the preparation of the compound and salts; (c) pharmaceutical compositions comprising the compound or salts; and (d) methods of use of such compositions.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: December 22, 2015
    Assignee: AbbVie Inc.
    Inventors: Jean-Christophe Califano, James J. Napier, Calvin L. Becker, Su Yu
  • Bicyclic carboxamide inhibitors of kinases
    Patent number: 9212192
    Abstract: Compounds of formula (I) or pharmaceutical acceptable salts are provided, wherein X1˜X5, R1˜R3, A, B, Z and n are defined in the description. And compositions containing said compounds, and the uses for inhibitors of kinases such as ALK, and the uses for treating cancer thereof are provided.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: December 15, 2015
    Assignee: AbbVie Inc.
    Inventors: Anil Vasudevan, Thomas Dale Penning, Huanming Chen, Bo Liang, Shaohui Wang, Fengchun Wu, Yan Shen, Cuihua Liu, Zhenguang Zou, Marina Pliushchev
  • Methods to control protein heterogeneity
    Patent number: 9206390
    Abstract: The instant invention relates to the field of protein production, and in particular to compositions and processes for controlling and limiting the heterogeneity of proteins expressed in host cells.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: December 8, 2015
    Assignee: AbbVie, Inc.
    Inventors: Lisa M. Rives, Cornelia Bengea, Xiaobei Zeng
  • Inhibitor compounds of phosphodiesterase type 10A
    Patent number: 9200005
    Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof: In formula I the variables X1 is CH or N, X2 is O or S and where R1, R2, R3, R4 and Q are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A. Thus, the invention also relates to the use of the compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.
    Type: Grant
    Filed: February 25, 2014
    Date of Patent: December 1, 2015
    Assignees: AbbVie Deutschland GmbH & Co. KG, AbbVie Inc.
    Inventors: Katja Jantos, Michael Ochse, Hervé Geneste, Jayne Froggett, Clarissa Jakob, Karla Drescher, Jürgen Dinges
  • Low acidic species compositions and methods for producing and using the same
    Patent number: 9200069
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: December 1, 2015
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Methods for transforming yeast
    Patent number: 9200270
    Abstract: This invention is directed to the transformation of yeast, and mutants thereof, by electroporation, which result in stably transformed yeast host cells that express recombinant products. This invention also is directed to transformed yeast cells and libraries.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: December 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Chung-ming Hsieh, Jonathan P. Belk, Jennifer M. Perez, Lorenzo Benatuil
  • Phosphine ligands for catalytic reactions
    Patent number: 9200021
    Abstract: The disclosure is directed to: (a) phosphacycle ligands; (b) catalyst compositions comprising phosphacycle ligands; and (c) methods of using such phosphacycle ligands and catalyst compositions in bond forming reactions.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: December 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Shashank Shekhar, Thaddeus S. Franczyk, David M. Barnes, Travis B. Dunn, Anthony R. Haight, Vincent S. Chan
  • Low acidic species compositions and methods for producing and using the same
    Patent number: 9200070
    Abstract: The instant invention relates to low acidic species (AR) compositions comprising a protein, e.g., an antibody, or antigen-binding portion thereof, and methods, e.g., cell culture and/or protein purification methods, for producing such low AR compositions. Methods for using such compositions to treat a disorder, e.g., a disorder in which TNF? is detrimental, are also provided.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: December 1, 2015
    Assignee: AbbVie, Inc.
    Inventors: Natarajan Ramasubramanyan, Lihua Yang, Matthew Omon Herigstad, Hong Yang, Kartik Subramanian, Xiaobei Zeng, Diane D. Dong, Wen Chung Lim, Kathreen A. Gifford, Zehra Kaymakcalan, Christopher Chumsae
  • Processes for the preparation of an apoptosis-inducing agent
    Patent number: 9199992
    Abstract: Provided herein is a process for the preparation of an apoptosis-inducing agent, and chemical intermediates thereof. Also provided herein are novel chemical intermediates related to the process provided herein.
    Type: Grant
    Filed: March 11, 2015
    Date of Patent: December 1, 2015
    Assignee: AbbVie Inc.
    Inventors: Vincent S. Chan, Alan C. Christesen, Timothy A. Grieme, Yi-Yin Ku, Mathew M. Mulhern, Yu-Ming M. Pu
  • ANTI-EGFR ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    Publication number: 20150337042
    Abstract: The invention relates to anti-epidermal growth factor (EGFR) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: March 20, 2015
    Publication date: November 26, 2015
    Applicant: ABBVIE INC.
    Inventors: Edward B. Reilly, Andrew C. Phillips, Lorenzo Benatuil, Fritz G. Buchanan, Jonathan A. Meulbroek, Chung-Ming Hsieh, Jennifer Perez
  • Human antibodies that bind human TNF-alpha and methods of preparing the same
    Patent number: 9193787
    Abstract: Methylglyoxal (MGO)-modified recombinant TNF-alpha antibodies (e.g., Adalimumab) are identified. MGO modification decreases binding between Adalimumab and TNF-alpha. Methods are disclosed for reducing the presence of MGO-modified antibodies in the production of Adalimumab TNF-alpha antibodies.
    Type: Grant
    Filed: October 23, 2014
    Date of Patent: November 24, 2015
    Assignee: ABBVIE INC.
    Inventor: Christopher M. Chumsae
  • Compounds as cannabinoid receptor ligands
    Patent number: 9193713
    Abstract: The present invention relates compounds of formula (I) wherein A and R1 are as defined in the specification, pharmaceutical compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and pharmaceutical compositions.
    Type: Grant
    Filed: October 7, 2008
    Date of Patent: November 24, 2015
    Assignee: AbbVie Inc.
    Inventors: William A. Carroll, Michael J. Dart, Arturo Perez-Medrano, Derek W. Nelson, Tongmei Li, Sridhar Peddi, Jennifer Frost, Teodozyj Kolasa, Bo Liu, Steven P. Latshaw, Xueqing Wang
  • Pump
    Patent number: D744005
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: November 24, 2015
    Assignee: ABBVIE INC.
    Inventors: Phil D. Anderson, Kevin Novak, Gurjinder Dhami, Scott Smieja, Matthew Svacina, Gary Friederichs
  • Interface portion of a pump
    Patent number: D746871
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: January 5, 2016
    Assignee: ABBVIE INC.
    Inventors: Phil D. Anderson, Kevin Novak, Gurjinder Dhami, Scott Smieja, Matthew Svacina, Gary Friederichs